Angus Dalgleish, MD, FRCP, FRACP - LDN 2023

Dr. Dalgleish trained at University College Hospital, then trained in internal medicine and oncology at hospitals in Brisbane and Sydney. He was Senior Clinical Scientist at the MRC Clinical Research Centre at Northwick Park, which led to the licensing of Revlimid (Lenalidomide) and Pomalidomide (Pomalyst) for myeloma and lymphoma. He was awarded the Joshua Lederberg prize in 2011 in recognition of this work.

Since 1991, he has been Professor of Oncology at St. George's University of London. During this time, he has focused on the immunotherapy of cancer, and has conducted numerous clinical trials involving a variety of vaccines and immunotherapy. Since 2001, he has been the Principal of the Cancer Vaccine Institute, currently focusing on the revival of the Mycobacterium-based vaccines that were dropped by SR Pharma and now resurrected by Immodulon.

He is on numerous scientific advisory boards involving the development of vaccines and immunotherapy, including Celgene, Immodulon, Curevac, Bionor Pharma, and LDN Pharma. He was Chief Investigator of a randomised clinical trial in patients with metastatic pancreatic cancer for Immodulon (IMM-101) and Gemcitabine versus Gemcitabine alone, which has shown a significant survival advantage for the IMM-101 combination with no significant toxicities. (Dalgleish et al., BJC 2016). In addition, his observations that Revlimid is co-stimulatory when given with vaccines has been confirmed in a randomised study of a therapeutic vaccine for HIV, where it significantly increased the CD4 counts which have not responded to HAART or the vaccine alone.

1. Cancer and Case Studies
2. Long COVID and Case Studies